In November 2020, a review published in the journal Cardiovascular Diabetology highlighted the renoprotective benefits of sodium-glucose cotransporter 2 (SGLT2) inhibitors in type-2 diabetes patients, over a spectrum of cardiovascular and renal risk profiles.
According to the article, approximately 50% of people with type-2 diabetes develop some degree of renal impairment, with 20% of type-2 diabetes patients presenting with chronic kidney disease (CKD).
Glucose-lowering treatments have been shown to reduce the risk of nephropathy in people with type-2 diabetes– and recent cardiovascular outcomes trials have highlighted the ability of SGLT2 inhibitors to prevent end-stage kidney disease (ESKD) and acute kidney injury.
Research has demonstrated the renoprotective benefits of SGLT2 inhibitors across a spectrum of cardiovascular and renal risk profiles – even in patients with no renal damage at all. This suggests that SGLT2 inhibitors may not only prevent the progression of CKD, but also prevent the initial onset of CKD in people with type-2 diabetes.
